Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.98 |
| ▸ | TSHR | P16473 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | GABRP | O00591 | 1/20 | 0.98 |
| ▸ | GABRD | O14764 | 1/20 | 0.98 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.98 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.98 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.98 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.98 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.98 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.98 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.98 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.98 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.98 |
| ▸ | GABRE | P78334 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicuculline SCHEMBL29617593 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29652597 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5783586 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL8222 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5481014 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL16320040 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL7913545 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29366341 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29390611 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL28213750 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228644-A1 | NEURAL STEM CELL COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3801764-A1 | NEURAL STEM CELL COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISORDERS | The Regents of the University of California (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-2560008-B1 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INST SCI & TECH (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-9469653-B2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-10-18 | — | — | US | disclosed |
| US-9014430-B2 | Image analysis platform for identifying artifacts in samples and laboratory consumables | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140233797-A1 | IMAGE ANALYSIS PLATFORM FOR IDENTIFYING ARTIFACTS IN SAMPLES AND LABORATORY CONSUMABLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140142089-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-05-22 | — | — | US | disclosed |
| US-8644547-B2 | Image analysis platform for identifying artifacts in samples and laboratory consumables | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130046093-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-21 | — | — | US | disclosed |
| EP-2560008-A2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | Korea Institute of Science and Technology (KR) | 2013-02-20 | — | — | EP | disclosed |
| CN-101675922-A | Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use | SHISEIDO CO LTD | 2010-03-24 | — | — | CN | disclosed |
| WO-2008141438-A1 | GABAERGIC MODULATORS FOR TREATING AIRWAY CONDITIONS | SUNNYBROOK HEALTH SCIENCES CENTRE (CA) | 2008-11-27 | — | — | WO | disclosed |
| US-20080269304-A1 | Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use | SHISEIDO CO., LTD. (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080268439-A1 | ASSAY SYSTEMS AND METHODS FOR DETECTING MOLECULES THAT INTERACT WITH SK2 CHANNELS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20050250090-A1 | Assay systems and methods for detecting molecules that interact with SK2 channels | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| CN-1655813-A | Parakeratosis inhibitor, pore-shrinking agent, and external preparation for skin | SHISEIDO CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| US-20050152930-A1 | Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use | SHISEIDO CO., LTD. | 2005-07-14 | — | — | US | disclosed |
| EP-1550459-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO COMPANY LIMITED (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005043973-A2 | ASSAY SYSTEMS AND METHODS FOR DETECTING MOLECULES THAT INTERACT WITH SK2 CHANNELS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-19 | — | — | WO | disclosed |
| EP-0533352-A2 | Gaba receptor agonists to treat bladder instability | LYNXVALE LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142089-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | PSEN2, PSEN1, GRN | CYP3A4 4679/4885CYP2C9 4609/4885CYP2C19 4499/4885 |
| US-20130046093-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | PSEN2, PSEN1, GRN | CYP3A4 4679/4885CYP2C9 4609/4885CYP2C19 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.